EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

BioAge Labs, Inc (BIOA) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of BioAge Labs, Inc $5.94, price $7.89, upside -24.7%, quality 37 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US09077V1008

BL BioAge Labs, Inc logo Thin data Sep 23, 2026

BioAge Labs, Inc

BIOA · US

Weak valuationQuality is weak on top of the rich price.

!Fair value $5.94 · Overvalued (−25%)
!Quality 37/100
!Weak Growth
!Low debt · negative free cash flow
!Trails peers (2/8)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch BioAge Labs, Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$25.83 $3.04 Fair Value $5.94 Sep 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

24‑month range $3.04 – $25.83 · fair‑value band $3.92 – $7.42 · the $7.89 price screens above the $5.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.

Follow BioAge Labs in your weekly email

Every Wednesday you see whether BioAge Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.

Show more

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Stock analysis

BioAge Labs, Inc (BIOA) currently trades at $7.89, while our model-based Fair Value estimate is $5.94, implying the stock looks roughly 32.8% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $3.92 (bear) to $7.42 (bull), the price of $7.89 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

BioAge Labs, Inc reported revenue of $9.0M in FY2025 versus $14.9M in FY2017, a compound −6.1%/yr. Reported net income was −$80.6M in FY2025.

Key figures

Market cap $968M · P/S ratio 93.9 · EPS (TTM) $−2.40 · Return on equity −26.0% · Return on assets (EBIT) −108% · Operating margin −915% · Revenue (TTM) $10.3M · Revenue growth (YoY) +91.0%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 69% below its 52-week high and 60% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −25%, BIOA screens richer than that median.

Fair Value models

Bear $3.92 Fair Value $5.94 Bull $7.42
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $3.06 $4.10 $6.12 54
All 1 models by family
Asset-Based
NCAV (Graham) $3.06 $4.10 $6.12 54

Open the full fair value analysis →

Notify me when BIOA reaches fair value

Put BIOA on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 37/100

Of which business quality 41 · Market factors (momentum, volatility) 29

Profitability 1
Margins and returns on capital today
Quality Growth 33
Are margins and returns improving?
Cashflow 11
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 33
Price trend over the last 3–12 months (market factor)
52W Momentum 54
Distance to the 52-week high (market factor)
Net Issuance 72
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,545.1% (2013) → −1,031.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

BIOA screens 33% overvalued. Compare with Merck KGaA →

Compare BioAge Labs, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 629 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −25% · Below median
Profitability
Return on assets −17% · Bottom 25%
Growth and dividend
Revenue growth 91% · Top 25%
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 3.56× · Priciest 25%
P/S (TTM) 93.87× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)100 · sector 20
PAST (return on equity)0 · sector 27
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.72 ¥50.29 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,846 ₹1,979 +7%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

BioAge Labs, Inc · Fair Value
$5.94 −33%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "BioAge Labs, Inc Fair Value". https://www.fairvalue-calculator.com/stock/BIOA

Frequently asked questions

Is BioAge Labs, Inc (BIOA) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $5.94 versus a price of $7.89, about −25% upside (overvalued).
What is the fair value of BIOA?
Our model-based fair value for BioAge Labs, Inc is $5.94 (as of Sep 23, 2026), built from audited fundamentals. The current price: $7.89.
What is the quality score of BIOA?
BioAge Labs, Inc has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioAge Labs, Inc (BIOA)?
Our model-based price target is the fair value of $5.94 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $3.92, optimistic scenario $7.42. It is a calculation from audited fundamentals, not an analyst target.
What is the BioAge Labs, Inc stock forecast for 2026?
Our models put fair value at $5.94, about −25% upside versus a price of $7.89 (overvalued). Cautious scenario $3.92, optimistic scenario $7.42. The calculation is refreshed regularly with new filings.
What is the revenue of BioAge Labs, Inc (BIOA)?
BioAge Labs, Inc reported trailing-twelve-month revenue of about $10.3M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of BioAge Labs, Inc (BIOA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioAge Labs, Inc it is $5.94 per share (as of Sep 23, 2026), against a price of $7.89. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is BioAge Labs, Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, BIOA trades above its calculated fair value: price $7.89, fair value $5.94, a gap of about −25% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIOA?
No. The price is what the market pays today ($7.89); the fair value is what the company's own numbers justify ($5.94). For BioAge Labs, Inc the two are $1.95 per share apart. That gap is exactly why we show both numbers side by side.
How much is BioAge Labs, Inc worth?
The market values BioAge Labs, Inc at about $968M (market capitalisation, as of Sep 23, 2026). Per share that is $7.89; our models calculate a fair value of $5.94 per share.
What do the bullish and bearish scenarios say about BIOA?
Our models span a range for BioAge Labs, Inc: cautious scenario $3.92, base $5.94, optimistic $7.42 per share (as of Sep 23, 2026, price $7.89). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BioAge Labs, Inc (BIOA)?
Balance-sheet figures for BioAge Labs, Inc (as of Sep 23, 2026): return on equity −26.0%, debt of 0.01 per unit of equity. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is BIOA from its 52-week high?
BioAge Labs, Inc trades at $7.89, about 69% below its 52-week high of $25.10 and 60% above the low of $4.94 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $5.94 is for.
Which stocks are comparable to BioAge Labs, Inc?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioAge Labs, Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $7.89, calculated fair value $5.94 (−25%), Quality Score 37/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIOA calculated?
We run BioAge Labs, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $5.94, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. BioAge Labs, Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioAge Labs, Inc (BIOA)?
The closing price on Sep 23, 2026 was $7.89. Our model-based fair value is $5.94, about −25% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioAge Labs, Inc right now?
The price sits above even our optimistic bull case ($7.42). The favourable scenario is already priced in. Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($3.92 to $7.42) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of BioAge Labs, Inc

How large is the market capitalisation of BioAge Labs, Inc (BIOA)?
The market capitalisation of BioAge Labs, Inc is $968M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioAge Labs, Inc (BIOA)?
The price-to-sales ratio of BioAge Labs, Inc is 93.9 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BioAge Labs, Inc (BIOA)?
Earnings per share at BioAge Labs, Inc are $−2.40. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of BioAge Labs, Inc (BIOA)?
The return on equity (ROE) of BioAge Labs, Inc is −26.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioAge Labs, Inc (BIOA)?
On an EBIT basis the return on assets of BioAge Labs, Inc is −108% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioAge Labs, Inc (BIOA)?
The operating margin of BioAge Labs, Inc is −915% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioAge Labs, Inc (BIOA)?
Revenue at BioAge Labs, Inc is growing +91.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does BioAge Labs, Inc (BIOA) generate?
The free cash flow of BioAge Labs, Inc is −$82.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does BioAge Labs, Inc (BIOA) hold?
BioAge Labs, Inc holds more cash than debt, $183M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch BioAge Labs, Inc in the live analysis

One click puts BioAge Labs, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.